Host: Raj Chovatiya, MD, PhD Guest: Christopher Bunick, MD, PhD, FAAD The American Academy of Dermatology recently updated the treatment guidelines for atopic dermatitis to include the latest systemic therapies, like biologics and JAK inhibitors. Since these new standards of care could offer improved outcomes for our patients with atopic dermatitis, Dr. Raj Chovatiya speaks with Dr. Christopher Bunick about what the new guidelines recommend and how we can incorporate them into clinical practice. Dr. Bunick is an Associate Professor of Dermatology at the Yale School of Medicine.

Guest: Rasheed A. Gbadegesin, MD, MBBS A new study by the H3 Africa Kidney Research Network found that APOL1 variants are a major risk factor for chronic kidney disease. Additionally, these variants are particularly prevalent among West Africans. Dr. Rasheed Gbadegesin dives into these findings and explains how they could contribute to preventive measures and improved outcomes in patients of African ancestry. Dr. Gbadegesin is the Director of the Office of Physician-Scientist Development at Duke University School of Medicine.

Host: Jennifer Caudle, DO Guest: Steven R. Feldman, MD, PhD The American Academy of Dermatology recently updated their guidelines regarding the treatment of moderate-to-severe atopic dermatitis to expand the recommended use of systemic therapies like biologics and JAK inhibitors. To help ensure our approach is up to date, Dr. Jennifer Caudle speaks with Dr. Steven Feldman about the new guidelines and how we can implement them into clinical practice. Dr. Feldman is a Professor of Dermatology, Pathology, Social Sciences and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Guest: Mohamed Ibrahim, MB, BCh IgA nephropathy (IgAN) is a rare autoimmune kidney disease in which IgA deposits damage kidney filters, causing symptoms like proteinuria and swelling. While symptoms can overlap with other kidney diseases, IgAN presents challenges of its own. Learn about the unique characteristics of IgAN with Dr. Mohamed Ibrahim, an Assistant Professor of Transplant Nephrology at the University of Maryland School of Medicine.

Guest: Jennifer Moore, MS, RDN, CSR, LDN Host: Charles Turck, PharmD, BCPS, BCCCP IgA nephropathy, or IgAN, is a rare kidney disease that requires dietary changes to maintain kidney health and function while supporting other organ systems. Learn about the most crucial dietary considerations for these patients from Jennifer Moore, a renal nutrition expert.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John Hertig PharmD, MS, CPPS Not only does intraoperative opioid waste have serious environmental, regulatory, and financial costs, but it can also threaten the quality of patient care and safety. Fortunately, implementing strategies like ready-to-administer syringes with small doses can improve surgical protocols, patient outcomes, and overall healthcare efficiency. Joining Dr. Charles Turck to discuss how we can address and prevent the critical impacts of opioid waste is Dr. John Hertig, Associate Professor of Pharmacy Practice and Department Chair at Butler University College of Pharmacy and Health Sciences.

Host: Gates B. Colbert, MD Guest: Kelly Helm Over 35 million people in the United States suffer from some form of chronic kidney disease, but many of them lack the support and education to navigate their condition and receive the best possible care. After her daughter was diagnosed with a rare kidney disease, Kelly Helm discovered the many obstacles associated with management and treatment. Hear from Kelly as she sits down with Dr. Gates Colbert to share what she’s learned as a parent, caregiver, and advocate. Kelly is the Executive Director of Patient Engagement at NephCure, a nonprofit organization dedicated to supporting and empowering patients with rare kidney diseases.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sara Enslin, PA Current colorectal cancer (CRC) screening rates are low, putting patients at risk of developing more advanced disease and even increased mortality. Primary care physicians play a critical role in reversing this troubling trend, which is why Dr. Charles Turck speaks with Ms. Sarah Enslin about strategies for improving adherence to CRC screening in the primary care setting. Ms. Enslin is a physician assistant at the University of Rochester Medical Center in Rochester, New York.

Host: Matt Birnholz, MD For patients at average risk of colorectal cancer (CRC), the United States Preventative Services Task Force recommends screening with either the multi-target stool DNA test or fecal immunochemical test. But in light of new performance data that compared a multi-target stool DNA test and a fecal immunochemical test, a poster presented at the 2024 Digestive Disease Week conference re-evaluated the benefits and harms associated with each test. Tune in to learn more about the findings and their implications for CRC screening.

Host: Matt Birnholz, MD The United States Preventative Services Task Force endorses multiple screening options for patients at average-risk of colorectal cancer (CRC). These options include colonoscopy, multi-target stool DNA, and the fecal immunochemical test. However, performance data for non-endorsed options like multi-target stool RNA and blood-based screening tests have recently been published. That’s why a recent poster presented at the 2024 Digestive Disease Week conference compared the benefit-to-harm ratio for guideline-endorsed versus non-endorsed CRC screening tests. Tune in to learn more about the findings and their implications for CRC screening.